Biogen, Array strike preclinical autoimmune disease pact

Array BioPharma ($ARRY) has formed a drug discovery pact with Biogen Idec ($BIIB) to develop inhibitors targeting a novel kinase for the treatment of autoimmune disorders. The collaboration target and lead inhibitors were discovered through Array's proprietary Kinase-Directed Phenotypic Screening Platform. Under the terms of the agreement, Biogen will be responsible for all aspects of clinical development and commercialization and fund three years of research. More

Read more on